Toboroz
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
NCT07638553· 3. fázis· Centre Hospitalier Universitaire de Nīmes· Forrás
Toboroz
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
JAK Inhibitor Dose TAPering Strategy Study
NCT06687551· 4. fázis· University Hospital, Toulouse· Forrás
Toboroz
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
NCT06471465· 3. fázis· Institut Cancerologie de l'Ouest· Forrás
Toboroz
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864· 2. fázis· UNICANCER· Forrás
Toboroz
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
2023-504022-19-01· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
NCT05532813· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· 3. fázis· OSE Immunotherapeutics· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
2023-503697-21-01· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Toboroz
Impact of local tissue inflammation on intramyocardial conduction pathways post percutaneous valve : evaluation by positron emission tomography on exploratory cohort
2024-514587-44-00· 2. fázis· Centre Hospitalier Regional Et Universitaire De Brest· Forrás
Toboroz
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.
2023-506590-35-00· 2. fázis· Centre Leon Berard· Forrás
Toboroz
Amoxicillin alone versus amoxicillin/clavulanate for community-acquired pneumonia in patients aged 65 years or older, and hospitalized in a non-intensive care unit ward: a non-inferiority randomized controlled trial _ CAPTAIN
2023-503645-63-00· 3. fázis· Centre Hospitalier Universitaire De Nantes· Forrás
Fut, nem toboroz
TocilizuMab discontinuAtion in GIant Cell Arteritis
2023-505515-21-00· 3. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Toboroz
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype
NCT06269900· 3. fázis· Nantes University Hospital· Forrás
Fut, nem toboroz
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386· 4. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome and receiving an allogeneic stem cell transplantation with an unrelated matched donor after a reduced intensity conditioning regimen
2023-504555-27-00· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Fut, nem toboroz
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803· 3. fázis· AstraZeneca· Forrás
Toboroz
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
NCT05627375· 3. fázis· Centre Hospitalier Universitaire de Saint Etienne· Forrás
Toboroz
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
NCT05758831· 3. fázis· Rennes University Hospital· Forrás
Toboroz
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
NCT05732727· 3. fázis· University Hospital, Tours· Forrás
Fut, nem toboroz
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis
NCT05428488· 3. fázis· University Hospital, Montpellier· Forrás
Toboroz
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
NCT05180825· 2. fázis· University Hospital, Strasbourg, France· Forrás
Fut, nem toboroz
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
2024-512634-15-00· 1/2. fázis· LYSARC· Forrás
Fut, nem toboroz
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04870203· 3. fázis· University Hospital, Bordeaux· Forrás
Fut, nem toboroz
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156· 3. fázis· Geron Corporation· Forrás
Fut, nem toboroz
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
NCT03806309· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Toboroz
A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
NCT07856329· 2/3. fázis· Genethon· Forrás
Toboroz
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
NCT04319627· 3. fázis· Ottawa Hospital Research Institute· Forrás
Fut, nem toboroz
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772· 3. fázis· Acerta Pharma BV· Forrás
Toboroz
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
NCT03583710· 3. fázis· M.D. Anderson Cancer Center· Forrás
Fut, nem toboroz
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
NCT03323476· 3. fázis· Centre Hospitalier Departemental Vendee· Forrás
Toboroz
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224· 2. fázis· Apollomics Inc.· Forrás
Fut, nem toboroz
Paediatric Hepatic International Tumour Trial
NCT03017326· 3. fázis· University of Birmingham· Forrás
Lezárult
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
NCT00470223· 3. fázis· UNICANCER· Forrás